SCHEMBL3977063

SCHEMBL3977063

COC(=O)c1occ(-c2ccccc2)c1-c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.45
PTGS1 P23219 1/20 0.45
HTT P42858 1/20 0.44
ALDH1A1 P00352 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
HPGD P15428 1/20 0.43
PRKCZ Q05513 1/20 0.43
EGFR P00533 1/20 0.43
TSHR P16473 1/20 0.43
GABRA1 P14867 1/20 0.42
GABRG2 P18507 1/20 0.42
GABRB3 P28472 1/20 0.42
GABRA5 P31644 1/20 0.42
GABRA3 P34903 1/20 0.42
FGFR1 P11362 1/20 0.42
SRC P12931 1/20 0.42
FGFR2 P21802 1/20 0.42
FGFR4 P22455 1/20 0.42
FGFR3 P22607 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3975197 0.84 SLC6A3 (0.51) LMNAALDH1A1HPGDMAPTSMN1; SMN2
SCHEMBL3977057 0.83 PTGS1 (0.42) LMNAPTGS1HTTALDH1A1MEN1
SCHEMBL28962190 0.83 SLC6A4 (0.45) LMNAPTGS1HTTALDH1A1MEN1
SCHEMBL3974640 0.81 HTT (0.42) LMNAPTGS1HTTALDH1A1MEN1
SCHEMBL2097892 0.81 HNF4A (0.43) LMNAHTTALDH1A1MEN1KMT2A
SCHEMBL3977117 0.80 ALDH1A1 (0.48) LMNAPTGS1ALDH1A1MEN1KMT2A
SCHEMBL3979178 0.80 L3MBTL1 (0.44) LMNAHTTALDH1A1MEN1KMT2A
SCHEMBL3981715 0.79 PTGS1 (0.41) LMNAPTGS1ALDH1A1MEN1KMT2A
SCHEMBL3983743 0.79 HTT (0.40) LMNAPTGS1HTTALDH1A1MEN1
SCHEMBL3978078 0.79 ALDH1A1 (0.51) LMNAHTTALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514452-B2 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD (JP) 2009-04-07 US disclosed
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-04 US disclosed
EP-1489077-A1 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2004-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same GLP1R, GCGR, GPR119 LMNA 2180/4885PTGS1 1730/4885HTT 1770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.